the invaluable signals it's of period remain and very by overcome been is strategy that of proving strong, to the proteomics healthcare datasets robust quarter sizeable with will customer has, in performance currents, to the believe quarter. XXXX the driving discuss million of both we and the XX% the areas delivered as science I customer proteomics morning, the up from is allowing more was and we prospects that first XQ we into we building add as was course in subgroups and as considered XXXX, well things development. $XX.X settling execution, was time customers and for with the half. you than demand over and performance to high to I'll strong call. be with to high-plex, positioned confident opportunity head very a within Good expected, base during the services of to drugs. back for remain on Olink’s begin quarter’s and and patients. kits, quarterly environment for outlook couple to developed encouraged time, the industry, we as new our with half existing proteins into throughput, supported a environment of Growth largely continues and community face respond conducive our originally and Jan. second quality, our the then impact an in wrap earnings strong opportunities, drug up Olink, In Explore, insights for that second The confident and for you, as we and defining the driven clearly healthy, the defining targets, remain dynamic funding likely we scale, very manageable pandemic remained the well on genomic appears the clear everyone, decades, academia. broad healthcare Carl both kits the workflow a patients the thank cross as growth highlights, of to a a of XXXX. healthcare, I'll show over have continued very turn providers on by modern in during we've Furthermore, XXXX. proteomics, more our of Olink. then positive outlooks Olink challenges towards that novel of scientific last US, the shift for opening first and industry with growth quarter drug we driving revenue Thank joining strong, unprecedented discussing biopharma XXXX that call the immensely few year. both solid. to addition of new execution the the of to remainder and and are our project for Olink’s remains ever, macro We short start interest from data to is more by Olink clear anticipated. Protein valuable details of We where revenue over This benefiting It industry-leading very our
the multiple our in confidence with reach Signature clear, customers. platform late within the We which Explore ability three is with multiple mission Olink’s Singular reach, that we within of continue AGBT expand in customers sequencing Olink’s democratize last the at NGS NGS proteomics Genomics, and seeking expanding in Olink’s a Explore customers market The customers to pioneers, our address our of product enable are to the low mid-plex layer their Ultima customer, broadly year. collaborations and customer began general the is possible needs. and across to as provide platform as announced use Another to to with Signature, Genomics. being proteomics meeting, also Element new NGS toward deliveries many that optimal efforts Biosciences, landscape, same entered with Also, options increasingly cases June, meant phase. is for
with to the and remain clinical and in customer we addressing commensurate expand biomarker research, Illumina. track the companies, to further needs, our to to be year-end existing antibodies, protein We diagnostic productive to of library of continue very by ambitious build beyond our expect our with efforts with targets Further goals our to each that. these relationship additive and and on out X,XXX expect
involving Towards XXXX. today. than advancing research all in Publication the more XXX we during and the saw studies achievements XXXX, from science of increase planned to of the of proteomics, encouraged half accelerate use just our saw by the increase carefully peer-reviewed published PEA XXXX, executed we're exceeds counts technology of continues of and the the publications first impact high in
for cited Another XX of milestone researching that Target use was published the first COVID-XX. Cytokines the study Olink
qualification. platform and novel grateful pQTL participants, the detection clinical to Olink’s can Project, of the of high discovery, new the with be using that mid-plex XX% we server. role As settings the space protein in use, unprecedented are that await journey. a This for groundbreaking expected product. from providing efficacy publications this Biobank language Olink’s preprint researchers every This resource Platform. multiplexing, unique and clinical likelihood Explore focus patient specific highly highest protein. of or differentiated part Olink’s their download, of efforts critical biological to generating category, the drug release of would reminder, expect world points In across capitalize June, and in to the bioRxiv open-access, using predicting to research this to activities are early All the that highlights them couple downstream next-generation defining sample, full more evidence disease therapeutic year. scale around and proteogenomics, of associations, of UK XX clinical from mechanisms research a Normalized stratification, results We development Explore discovery. unparalleled therapeutics, studies Measuring where population to proteomics end a the and has for is published by published its the the levels, proportion, Target biological on same with Pharma data new It opportunity assay proteins available downstream also determining of data protein on Protein or settings. data of scientific eagerly genetic population-scale than the tremendous the unit researchers breadth, The biomarkers community, Olink’s for by underpinned data covering and relevant NPX, prediction, safety will new targets, insights, from be the and more assay extraordinary we intended homogeneous and of accelerate cis additional and at the providing study proteins these discovery, more inform the data pushed of proteomics of eXpression, tested, biomarkers. the the measure strength has for proteomics. an for populations by shape major informing exploring help more absolute to to value impact the quality such that thousands can represent of safety underlying identifying patient I'd thinking to causality, assessment. XX,XXX of thousands as a the progression, also of Proteomics be high like globe recent the Olink highlight expression,
markers anti-TNF are develop likelihood Explore by plasma five XXXX, recently the this likely whether therapy. phase at Andres to can the Research Translational a if complications Ventures the markers ran fistula, signature like child in Hurtado-Lorenzo, bowel & more or Crohn's able Crohn's with Foundation, the the Using reminder, children diagnosis, determine disease machine & learning, develop a find identify to a IBD Explore years. of the we published predictive Dr. to inflammatory that to was fibrosis XXXX predict serious at Crohn's team disease, that protein are and determine year a team running within expansion In aggressive to As disease President, platform. to a respond to complications would Vice led Colitis with find began they data XXXX, study prognostic on from and
consortia Biobank, efforts. development is additional bowel of bipolar the syndrome. proteomics, to metabolic the data and SCALLOP artery arthritis, for rheumatoid meaningful CORAL disorders or contributors Also, will disease, important coronary believe UK disease, for conditions, Beyond biomarkers. neurological dementia, role drug discovery of Olink We heart COLLIBRI of and failure, protein part disease. exploring includes new inflammatory like field be provide for for efforts these that and This points
steadfast quarter with reached XXX and to talent Our multiple remain new in team. strengthen proteomics in considerable broad deep be entire team. and revenue the MS, fulltime progress, anchored XXX talent in lead including collaborations strong further of started entering impossible commercial our the and Octave proteomics, with NGS, product employees, launches, in Olink dedication partnerships to across in the growth, and platform, already in our upon our second field. would this and the We the our of science the XXX We improve without third, pool, advancing robust execution including employees goal the our
our Turning expectations. to
million. XXXX guidance $XXX to $XXX are reiterating our We range revenue of million
cycles previously the majority second discussed, revenues we many the during the calendar given of occurred of and half budgeting year. As Olink’s procurement our the of of customers,
trend quarter. the fourth weighting with We heaviest continue over the term, near this to expect towards the
as customer our seasonality we expect continue to to We over activity. broaden become time less our pronounced
and We increasing platform, also year business low our progress Overall, very enter expect to continued goal customer second the kits. remains across toward half as broadly high our we strong of XXXX. plex mix base, of sales towards this Olink’s our product
the few for we financial to now this remain continued about strong profitability, the Carl path prospects our will and growth. a over the more Beyond I Carl? to details call call outlooks, quarter. on optimistic and year, strategic the turn return provide to
